N-Terminal domain antiandrogen
N-Terminal domain antiandrogen | |
---|---|
Drug class | |
![]() EPI-001, the first major N-terminal domain AR antagonist to be developed. | |
Class identifiers | |
Synonyms | N-Terminal domain AR antagonists; AR NTD antagonists |
Use | Prostate cancer |
Biological target | Androgen receptor |
Legal status | |
In Wikidata |
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
See also
- Androgen deprivation therapy
- 5N-Bicalutamide
References
- v
- t
- e
Androgens and antiandrogens
(incl. AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptor antagonists | |||||
---|---|---|---|---|---|
Steroidogenesis inhibitors |
| ||||
Antigonadotropins |
| ||||
Others |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e